Analyzing Circulating Tumor Cells in Prostate Cancer
Author Information
Author(s): Welsch Eva, Bonstingl Lilli, Holzer Barbara, Schuster Eva, Weiß Esther, Zaharie Alexandru-Teodor, Krainer Michael, Fischer Michael B., El-Heliebi Amin, Zeillinger Robert, Obermayr Eva
Primary Institution: Medical University of Vienna
Hypothesis
Can circulating tumor cells (CTCs) serve as a reliable prognostic marker in both localized and metastatic prostate cancer?
Conclusion
The study found that CTC analysis can effectively detect prostate cancer markers, providing valuable diagnostic information for both localized and metastatic cases.
Supporting Evidence
- CTCs were found in 87.0% of metastatic prostate cancer patients.
- An increase in positive transcripts was observed after radiation therapy in localized prostate cancer patients.
- PSA and PSMA positivity were associated with shorter overall survival in metastatic patients.
Takeaway
Doctors can find tiny cancer cells in the blood of prostate cancer patients to help understand how the disease is doing and if treatments are working.
Methodology
Blood samples were taken from patients with localized and metastatic prostate cancer, and CTCs were isolated and analyzed using qPCR and RNA in-situ hybridization.
Potential Biases
Potential bias in patient selection and the reliance on specific detection methods may affect the results.
Limitations
The study's findings may not be generalizable due to the small sample size and specific patient demographics.
Participant Demographics
Patients included 15 with localized intermediate/high-risk prostate cancer and 23 with metastatic prostate cancer.
Statistical Information
P-Value
0.020
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website